Propranolol for treatment of ulcerated infantile hemangiomas - 10/08/11

Doi : 10.1016/j.jaad.2010.12.040

Mélanie Saint-Jean, MD ^a, Christine Léauté-Labrèze, MD ^b, Juliette Mazereeuw-Hautier, MD ^c, Nathalie Bodak, MD ^d, Dominique Hamel-Teillac, MD ^d, Ingrid Kupfer-Bessaguet, MD ^e, Jean-Philippe Lacour, MD ^f, Michaël Naouri, MD ^g, Pierre Vabres, MD ^h, Smail Hadj-Rabia, MD ^d, Jean-Michel Nguyen, MD ⁱ, Jean-François Stalder, MD ^a, Sébastien Barbarot, MD ^a,^⁎
Groupe de Recherche Clinique en Dermatologie Pédiatrique
^a Department of Dermatology, Hôtel-Dieu, 44093 Nantes, France
^b Department of Dermatology, Hôpital Pellegrin, 33076 Bordeaux, France
^c Department of Dermatology, Hôpital Larrey, 31059 Toulouse, France
^d Department of Dermatology, Hôpital Necker, Centre de Référence des Maladies Génétiques à Expression Cutanée, Assistance Publique–Hôpitaux de Paris, 75015 Paris and Université Descartes Paris V, 75005 Paris, France
^e Department of Dermatology, Hôpital de Cornouaille, 29107 Quimper, France
^f Department of Dermatology, Hôpital Archet-2, Centre Hospitalier Universitaire de Nice, 06202 Nice, France
^g Department of Dermatology, Centre Hospitalier Universitaire, 37044 Tours and Laser Center, 94130 Nogent-sur-Marne, France
^h Department of Dermatology, Centre Hospitalier Universitaire, 21079 Dijon, France
ⁱ PIMESP, Hôpital Saint-Jacques, 44200 Nantes, France

Reprint requests: Sébastien Barbarot, MD, Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 Nantes Cedex, France.

Abstract

Background

Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH.

Objective

To evaluate our experience of propranolol in the management of ulcerated IH.

Methods

A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews.

Results

Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations (P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases.

Limitations

This was a retrospective uncontrolled study.

Conclusion

Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH.

Le texte complet de cet article est disponible en PDF.

Key words : infantile hemangioma, propranolol, ulceration

Abbreviations used : FPDL, IH

Plan

Follow-up and efficacy assessment

Statistical analyses

Results

Patient characteristics at baseline

Tolerance and treatment efficacy

Discussion

	Funding sources: None.
	Conflicts of interest: None declared.

Export

Vol 64 - N° 5

P. 827-832 - mai 2011 Retour au numéro

Article précédent

Notice to Authors: Journal Contact Information

| Article suivant

Propranolol, a very promising treatment for ulceration in infantile hemangiomas: A study of 20 cases with matched historical controls
Denise Josephina Johanna Hermans, Ingrid Mathilde van Beynum, Leonardus Jan Schultze Kool, Peter Cornelius Maria van de Kerkhof, Marcus Henricus Wilhelmus Andreas Wijnen, Catharina Joanna Maria van der Vleuten

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Propranolol for treatment of ulcerated infantile hemangiomas - 10/08/11

Abstract

Background

Objective

Methods

Results

Limitations

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL